Targeted Oncology· @TargetedOnc · X·· 1 天前评分70
正文 · 原文
Strong VOLGA Phase III results at #ESMO26!
Perioperative EV + durvalumab in cisplatin-ineligible MIBC:
2-year EFS: 64% vs 45% (HR 0.51)
2-year OS: 78% vs 69% (HR 0.58)
pCR: 45% vs 10%
An important survival advance. Could this redefine care?
76 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA2按 Presidential Symposium I 对上
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.org来源：Targeted Oncology · x.com